|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 556 active entries
BIOPOLE CLERMONT LIMAGNE
SAINT BEAUZIRE, 63360
Phone: +33 473 33 90 24
Neuronax is a biotechnological company focused on the development and discovery of new candidate-drugs for neural repair in cases of traumatic or degenerative disorders of the nervous system. The company focuses particular affections for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our ambition is to improve the recovery of the functionality and the quality of life for patients.
Our lead product (NX210) is a very promising drug with a high potential in many neurological disorders. This is a peptide with multi-functional action and its efficacy is supported by several pre-clinical proof of concept studies. We observed in vivo its capacity to regrow the nerve fibers after traumatic spinal cord injuries and to support functional recovery. The properties of NX210, and its patented analogs, have driven us with a strong rational to investigate in neurological disorders as Multiple Sclerosis, Alzheimer, Parkinson,...
A Phase I clinical trial in patients with Spinal Cord Injury is now authorized by French and Belgian Health Authorities.
Last update of this entry: September 26, 2017